2024
Insulin Requirement and Infrainguinal Bypass Outcomes in Patients with Peripheral Arterial Disease
Alameddine D, Satam K, Slade M, Wang H, Mena-Hurtado C, Turner J, Inzucchi S, Ochoa Chaar C. Insulin Requirement and Infrainguinal Bypass Outcomes in Patients with Peripheral Arterial Disease. Annals Of Vascular Surgery 2024, 102: 25-34. PMID: 38307234, DOI: 10.1016/j.avsg.2023.11.044.Peer-Reviewed Original ResearchInsulin-requiring diabetes mellitusPeripheral arterial diseaseDiabetes mellitusInfrainguinal bypassInsulin requirementsArtery diseaseRisk of MALEBypass surgeryImpact of insulin useRates of primary patencyVascular Quality Initiative databaseOutcomes of patientsPeripheral arterial bypass surgeryInfrainguinal bypass surgeryStratification of patientsCrude rateElevated hemoglobin A1cArtery bypass surgeryAssociation of DMChronic limb-threatening ischemiaIncreased risk of MALEVascular Quality InitiativeLower extremity revascularizationAdverse limb eventsLimb-threatening ischemia
2022
Predictors of Major Adverse Limb Events After Infrainguinal Bypass in Patients with Diabetes
Alameddine D, Satam K, Slade M, Wang H, Mena-Hurtado C, Turner J, Inzucchi S, Chaar C. Predictors of Major Adverse Limb Events After Infrainguinal Bypass in Patients with Diabetes. American Heart Journal 2022, 254: 241. DOI: 10.1016/j.ahj.2022.10.026.Peer-Reviewed Original ResearchMajor adverse limb eventsLower extremity revascularizationPeripheral artery diseaseAdverse limb eventsInfrainguinal bypassInsulin useDiabetes mellitusLimb eventsVascular Quality Initiative databaseHigher major amputationObjective Diabetes mellitusOutcomes of patientsAssociation of diabetesLower primary patencyMajor risk factorMajor amputationPrimary patencyExtremity revascularizationInsulin therapyKidney transplantArtery diseaseGlucose controlA1c controlRisk factorsHigh risk
2020
Empagliflozin in Heart Failure
Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, Suda N, Siwakoti K, Ahmad T, Jacoby D, Riello R, Bellumkonda L, Cox Z, Collins S, Jeon S, Turner JM, Wilson FP, Butler J, Inzucchi SE, Testani JM. Empagliflozin in Heart Failure. Circulation 2020, 142: 1028-1039. PMID: 32410463, PMCID: PMC7521417, DOI: 10.1161/circulationaha.120.045691.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsCotransporter 2 inhibitorsNeurohormonal activationHeart failureRenal dysfunctionBlood volumeHeart failure-related outcomesPlacebo-controlled crossover studyType 2 diabetes mellitusProximal tubular siteHeart failure outcomesStable heart failureUrinary glucose excretionUric acid levelsElectrolyte wastingEmpagliflozin monotherapyOral empagliflozinPlacebo periodStudy drugGlucose excretionNatriuretic effectPotassium wastingTubular sitesDiabetes mellitusFractional excretion